

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 03/035105 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/39**

(21) International Application Number: PCT/CA02/01649

(22) International Filing Date: 23 October 2002 (23.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/330,476 23 October 2001 (23.10.2001) US

(71) Applicant (for all designated States except US): **CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER** [CA/CA]; 3755 chemin de la Côte Ste-Catherine, Montréal, Québec H3T 1E2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GALIPEAU, Jacques** [CA/CA]; 251, Morrison, Town of Mount-Royal, Québec H3R 1K7 (CA). **STAGG, John** [CA/CA]; 5245 Côte Ste-Catherine, Apt. 14, Montréal, Québec H3W 1M9 (CA).

(74) Agent: **OGILVY RENAULT**; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A NOVEL SYNTHETIC CHIMERIC FUSION TRANSGENE WITH IMMUNO-THERAPEUTIC USES

(57) Abstract: The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response in a patient.

WO 03/035105 A2

## A NOVEL SYNTHETIC CHIMERIC FUSION TRANSGENE WITH IMMUNO-THERAPEUTIC USES

### BACKGROUND OF THE INVENTION

#### 5 (a) Field of the Invention

The invention relates to a novel synthetic chimeric fusion gene and protein with immuno-therapeutic uses.

#### (b) Description of Prior Art

10 Research focusing on immunomodulation is attracting growing interest. DNA vaccines encoding for antigenic peptides have recently been developed as a novel vaccination technology against viral infections such as HIV (Ahlers JD. *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*. 94(20):10856-61, 1997 Sep 30.), as well as against cancer (Strominger JL., *Nature Medicine*. 1(11):1140, 1995 Nov). For these next generation of vaccines based on 15 poorly immunogenic antigens, there is a great need for powerful adjuvants, both strong and safe, that can be used to enhance the immune response. Although many adjuvants such as LPS, LT and CT are used experimentally today (Vogel FR. Powell MF., [Review] *Pharmaceutical Biotechnology*. 6:141-228, 1995), most of them comprise a toxic fragment 20 that is required for adjuvanticity, thus greatly hampering their clinical use.

The delivery of cytokine genes to enhance immune response to synthetic peptide vaccines may therefore represent an advantage over conventional adjuvants. Vaccination studies with genetically engineered 25 cancer cells secreting cytokines such as IL-4, IL-6, IL-7, INF- $\gamma$ , TNF- $\alpha$ , IL-12, GM-CSF or IL-2 (Dranoff G. *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*. 90(8):3539-43, 1993 Apr 15) (Irvine KR. *et al.*, *Journal of Immunology*. 156(1):238-45, 1996 Jan 1) have been shown to generate tumor-specific immune 30 responses. Several studies have shown in addition that co-expressing some of these cytokines generated synergistic antitumor effects. Comparing the adjuvant effects of several cytokines on DNA vaccines revealed that the co-expression of GM-CSF and IL-2 genes induced the higher antibody titers and T cell proliferation response than other cytokine

genes tested to date (Pan CH. *et al.*, [Review] *Journal of the Formosan Medical Association*. 98(11):722-9, 1999 Nov). The co-expression of GM-CSF and IL-2 by tumor cells was also shown to induce potent synergistic antitumor effect (Lee SG. *et al.*, *Anticancer Research*. 20(4):2681-6, 2000 Jul-Aug).

A bifunctional chimeric gene product borne from the fusion of GM-CSF and IL-2 cDNA may therefore display novel and potent immunostimulatory properties that could supersede that seen with either protein alone or expressed in combination. Granted, such a fusion sequence would be bereft of a true physiological role. However, the aim of cancer immunotherapy is to elicit as violent an immune reaction as possible against tumor. The idea of fusing GM-CSF with an interleukin is viable. As an example, the proprietary PIXY321 recombinant protein marketed by Immunex® is a fusion of GM-CSF and IL-3 (Curtis BM. *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*. 88(13):5809-13, 1991 Jul 1). This molecule was marketed as a stimulator of hematopoietic recovery from chemotherapy toxicity. Its successful bioengineering demonstrates the feasibility of fusing GM-CSF with interleukins.

GM-CSF was first described as a growth factor for granulocyte and macrophage progenitor cells. However, GM-CSF is also an important mediator for inflammatory reactions produced by T lymphocytes, macrophages and mast cells present at sites of inflammation (reviewed in Demetri GD. Griffin JD., [Review] *Blood*. 78(11):2791-808, 1991 Dec 1). GM-CSF is a strong chemoattractant for neutrophils. It enhances microbicidal activity, phagocytotic activity and cytotoxicity of neutrophils and macrophages. An important feature of GM-CSF is that it greatly enhances the state of antigen presentation on dendritic cells, known to be crucial mediators of acquired immunity.

IL-2 on the other hand is an essential cytokine for the expansion of activated lymphocytes. IL-2 also supports the functional differentiation of mature lymphocytes, including CTL, NK cells and B cells. Moreover, IL-2 enhances CTL activity in activated primary CD8<sup>+</sup> T cells through the fact that IL-2 upregulates mRNA for FasL, perforin and granzyme B, all of

which are involved in the mechanism of CTL killing (Makrigiannis AP. Hoskin DW., *Journal of Immunology*. 159(10):4700-7, 1997 Nov 15). NK cells also proliferate and upregulate their cytolytic activity in response to IL-2, but require relatively high doses of IL-2 since they do not express the high affinity receptor complex.

It would be highly desirable to be provided with a novel synthetic chimeric fusion transgene and protein with immuno-therapeutic uses.

### **SUMMARY OF THE INVENTION**

It is reported herein the successful engineering of a DNA plasmid encoding for a novel chimeric protein borne from the fusion of murine GM-CSF and murine IL-2 cDNA. The fusion was generated by restriction enzyme cloning, and resulted in a truncated murine GM-CSF cDNA at the 5' end linked by a 3-bp linker to a the full length murine IL-2 cDNA at the 3' end. Moreover, the expression of this fusion sequence in B16 murine melanoma cells led to the secretion of a GMCSF/IL2 fusion protein that greatly reduced the tumorigenicity of the cells in a syngeneic mouse model.

The novel immunostimulatory properties of this fusion transgene lead to an anti-cancer therapeutic effect. The present application shown that the nucleotide sequence encoding for GIFT can be utilized as a therapeutic transgene for gene therapy of cancer. The present application proposes that the fusion transgene nucleotide sequence can be utilized for: (i) genesis of cell and gene therapy biopharmaceuticals for treatment of cancer, (ii) as a genetic immunoadjuvant to DNA vaccine technologies for use in the prevention and treatment of cancer or infectious diseases in humans and other mammals and, (iii) as a genetic immunoadjuvant for production of commercially valuable monoclonal and polyclonal antibodies in mammals.

In accordance with the present invention there is provided an immuno-therapy conjugate which comprises:

A-c-B

wherein:

A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and

5 c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues.

The conjugate in accordance with a preferred embodiment of the present invention, wherein the cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,  
10 IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

The conjugate in accordance with a preferred embodiment of the present invention, wherein the chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7,  
15 CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

20 The conjugate in accordance with a preferred embodiment of the present invention, wherein the interferon is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

25 In accordance with the present invention, there is provided an immuno-therapy fusion cDNA encoding the immuno-therapy conjugate of the present invention.

In accordance with the present invention, there is provided a vaccine adjuvant for DNA vaccination which comprises the conjugate of the present invention.

30 The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the vaccination is against an infectious organism.

The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the infectious organism is selected from the group consisting of: viruses, bacteries, mycobacteria, protozoa and prions.

5       The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the virus is selected from the group of Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

10       The vaccine adjuvant in accordance with a preferred embodiment of the present invention, wherein the vaccination is against malignancies, wherein the malignancies having at least one immunogen associated thereto.

15       In accordance with the present invention, there is provided a vaccine adjuvant for vaccination, which comprises the fusion cDNA of the present invention.

In accordance with the present invention, there is provided a method for reducing tumor growth in a patient, the method comprising administering to the patient a therapeutically effective amount of the conjugate of the present invention.

20       In accordance with the present invention, there is provided a method for reducing tumor growth in a patient, the method comprising administering to the patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention.

25       In accordance with the present invention, there is provided a method for inhibiting a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of the conjugate of the present invention.

30       In accordance with the present invention, there is provided a method to inhibit a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of the fusion cDNA of the present invention using a gene delivery technique.

The method in accordance with a preferred embodiment of the present invention, wherein the gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

5           In accordance with the present invention, there is provided a method to inhibit a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention.

10           In accordance with the present invention, there is provided a method to allow production of antigen-specific antibodies, the method comprising the administration of the species-specific fusion cDNA of claim 5 with the cDNA of the antigen or functional fragment thereof in experimental mammals.

15           In accordance with the present invention, there is provided a method to inhibit a viral infection in a patient, the method comprising administering to the patient a therapeutically effective amount of the fusion cDNA of the present invention using a gene delivery technique.

20           In accordance with the present invention, there is provided the use of a therapeutically effective amount of the conjugate of the present invention for reducing tumor growth in a patient.

25           In accordance with the present invention, there is provided the use of a therapeutically effective amount of the fusion cDNA of the present invention with a gene delivery technique for reducing tumor growth in a patient.

30           In accordance with the present invention, there is provided the use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention for reducing tumor growth in a patient.

          In accordance with the present invention, there is provided the use of a therapeutically effective amount of the conjugate of the present invention for inhibiting a viral infection in a patient.

          In accordance with the present invention, there is provided the use of a therapeutically effective amount of the fusion cDNA of the present

invention with a gene delivery technique to inhibit a viral infection in a patient.

5 In accordance with the present invention, there is provided the use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of the present invention to inhibit a viral infection in a patient.

10 In accordance with the present invention, there is provided the use of species-specific fusion cDNA of the present invention with the cDNA of antigen or functional fragment thereof to allow production of antigen-specific antibodies in mammals.

In accordance with the present invention, there is provided the use of a therapeutically effective amount of the conjugate of the present invention to improve immune response in a patient.

15 For the purpose of the present invention the following terms are defined below.

The term "subject" is intended to mean humans, mammals and/or vertebrates.

The term "functional fragment" is intended to mean a fragment that as conserved the same activity as the entire product.

20 **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 illustrates pGMCSF and pIL2 restriction enzyme maps;

Fig. 2 illustrates pGMCSF *EcoRI* digest on agarose gel;

Fig. 3 illustrates pGMCSF *EcoRV* digest on agarose gel, after *EcoRI* digestion;

25 Fig. 4 illustrates pIL2 *PstI* digest;

Fig. 5 illustrates pIL2 *EcoRI* digest (after *PstI* and S1 nuclease);

Fig. 6 illustrates the ligation of mGM-CSF to mIL-2;

Fig. 7 illustrates the ligation product *HindIII* digest;

Fig. 8 illustrates pJS330 confirmation digest;

30 Fig. 9 illustrates pJS330 restriction map;



Fig. 10 illustrates the amino acid sequence of a schematic fusion protein showing the positive sequencing of the fusion between mouse GM-CSF cDNA and mouse IL-2 cDNA;

5 Fig. 11 illustrates pJS330 *XhoI-HpaI* digest and AP2 *BamHI* digest;

Fig. 12 illustrates pJS4 confirmation digest;

Fig. 13 illustrates pJS4 restriction map;

Fig. 14 illustrates the secretion of the fusion protein by the JS4-transduced B16 cells;

10 Fig. 15 illustrates immunoblotting of the fusion protein with monoclonal antibodies against mouse IL-2 or mouse GM-CSF;

Fig. 16 illustrates the antitumor effect of the mGM-CSF/mIL2 fusion sequence when expressed in B16 melanoma cells;

15 Fig. 17 illustrates H&E staining of 5  $\mu$ m tumor sections from mice injected s.c. with  $10^6$  B16 cells engineered to secrete the mGMCSF/mIL2 fusion protein and GFP (Figs. 17B and 17D) or engineered to secrete GFP only (Figs. 17A and 17C); and

Fig. 18 illustrates the level of secretion of the fusion protein determined *in vitro* by ELISA.

## 20 DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a novel synthetic chimeric fusion transgene with immuno-therapeutic uses. It is therefore proposed that a bifunctional chimeric gene product borne from the fusion of GM-CSF and IL-2 cDNA may display novel and potent  
25 immunostimulatory properties that could supersede that seen with either protein alone or expressed in combination. Further, a fusion transgene will guarantee equimolar production of GM-CSF and IL-2 by all engineered cells. This is of significance, since independent transfer of IL-2 and GM-CSF is random in distribution, and it is only by chance that any  
30 gene-transfected cell express both protein.

## Materials and methods

Mouse IL2 and mouse GM-CSF cDNAs were purchased from the National Gene Vector Laboratories (NGVL, The University of Michigan). The synthesis of the fusion protein expression plasmid, namely pJS330, was as follow.

### Cloning pIL2

The 557-bp IL2 cDNA was excised by *Pst1-Swa1* restriction digest and ligated to the 3970-bp pEGFP-N1 (Clontech, Palo Alto, CA) fragment generated with *Not1*, Klenow fill-in and *Pst1*. This murine IL2 expression plasmid is referred to as pIL2 in the following text.

### Cloning pGMCSF

The 462-bp GM-CSF cDNA was excised by *Sal1-BamH1* restriction digest and ligated into the previously reported plasmid AP2 after *Xho1-BamH1* digest. Briefly, AP2 is a plasmid encoding for a bicistronic murine retrovector that incorporates a multiple cloning site, allowing insertion of a cDNA of interest. This murine GM-CSF expression plasmid is referred to as pGMCSF in the following text.

### Cloning pJS330

A 398-bp fragment from pGMCSF containing the cDNA for the mouse GM-CSF (truncated 33-bp prior to the stop codon) was excised by *EcoRI* followed by *EcoRV*. This truncated cDNA was ligated to the 5' end of the mL2 gene into pIL2. Prior to ligation, pIL2 was digested with *Pst1* (cutting 3-bp prior to IL2 start codon), followed by S1 nuclease to remove single stranded DNA, and *EcoR1* digest. 30µl of the 398-bp of pGMCSF was added to 55µl of the 4518-bp of pIL2 in the presence of DNA ligase for 16 hours at 14°C. Transformation of the ligation product was carried on in DH5α competent bacteria, and the bacteria subsequently were plated on agar. Colonies were grown for 12 hours and individual clones were picked and grew in LB broth for 12 hours. The DNA was then isolated using a commercial kit. The ligation product is referred to as pJS330 in the following text and encodes the fusion protein mGM-CSF/mL2.

The fusion mGM-CSF/mIL2 DNA coding sequence within pJS330 was subsequently sent for sequencing at the Guelph Molecular Supercentre (University of Guelph, Ontario). The two sequencing primers used (i.e. 5'-ACAGCCAGCTACTACCAGAC-3' [P1] (SEQ ID NO:1) and 5'-CGCTACCGGACTCAGATCTC-3' [P2] (SEQ ID NO:2)) were generated at the Sheldon Biotechnology Center (McGill University, Montreal).

#### Cloning pJS4

A 1090-bp fragment from pJS330 containing the fusion protein coding sequence was excised by *XhoI*-*HpaI* restriction digest and ligated into AP2 after *Bam**H*I, Klenow fill-in and *XhoI*. The ligation product is a retrovector plasmid referred to as pJS4 that allows for the expression of mGM-CSF/mIL2 fusion protein and GFP, as well as the generation of retrovectors when transfected into packaging cell lines.

#### Fusion Protein Expression

The expression and secretion of the mGM-CSF/mIL2 fusion protein was confirmed by ELISA. 5µg of the retrovector plasmid pJS4 or AP2 were digested with *Pst*I and co-transfected with 0.5µg of pJ6ΩBleo plasmid into GP+E86 retrovector packaging cells (American Type Culture Collection [ATCC]) with the use of Lipofectamine™ (Life Technologies, Inc.). Transfected cells were subsequently selected in DMEM media (10% heat-inactivated FBS plus 50 units/ml of Pen-Strep™) supplemented with 100µg/ml Zeocin™ (Invitrogen, San Diego, CA) for 4 weeks. Resulting stable producers generated ecotropic retroviral titers of 10<sup>5</sup> cfu/ml. GP+AM12 retrovector packaging cells (ATCC) were transduced with 10ml of fresh supernatant from pJS4 or AP2-transfected GP+E86 (plus 6µg/ml Lipofectamine) twice daily for 3 consecutive days. Resulting stable producers generated amphotropic viral titers of 10<sup>5</sup> cfu/ml. B16 murine melanoma cells were transduced with 10ml of fresh supernatant from pJS4 or AP2-transduced GP+AM12 (plus 6µg/ml Lipofectamine) twice daily for 6 consecutive days. One week later, 24 hours old supernatant was collected from B16-transduced cells, namely B16-JS4 and B16-AP2, and the cells counted by hemacytometer. The collected supernatant was frozen until thawed for ELISA detecting the presence of mGM-CSF protein (Biosource, San Diego, CA) or mIL-2 protein

(Biosource, San Diego, CA) in the supernatant according to the manufacturer's instructions.

### **B16 modified cells *in vivo* implantation**

5 Murine B16 engineered melanoma cells secreting the fusion protein and the reporter GFP (B16-JS4 cells) were injected subcutaneously (s.c.) in syngenic immunocompetent C57bl/6 mice. As a control, B16 melanoma cells expressing GFP only (B16-AP2 cells) were injected. Prior to implantation, the cells were trypsinized and centrifuged at 2000 rpm for 5 minutes in the presence of 10% FBS DMEM media.  
10 The cells were then resuspended in PBS. One million cells (in 100  $\mu$ l PBS) were injected per mouse using a 25<sup>5/8</sup> gauge syringe. Seven mice per group were injected subcutaneously and tumor volume was measured over time with a vernier caliper using the following formula: tumor volume = tumor length x (tumor width)<sup>2</sup> / 2.

### **15 Histology**

Control tumors were resected at day 20 post-implantation while tumors expressing the fusion protein were resected at day 52 post-implantation. Resected tumors were immediately fixed in 10% formalin, and subsequently embedded in paraffin, cut in 5 $\mu$ m-thick sections and  
20 stained with hematoxylin and eosin (H&E). Four sections per tumor were blindly examined microscopically by a pathologist to characterize the immune infiltration.

### **Results**

25 The cDNA for mouse GM-CSF and mouse IL2 were purchased from the National Gene Vector Laboratories and subsequently subcloned in two distinct expression plasmids, namely pGMCSF and pIL2 (Fig. 1). pGMCSF expression plasmid was first digested with *EcoRI* restriction enzyme and a sample run on agarose gel for confirmation (Fig. 2). In Fig. 2, column A is 1kb DNA ladder, column B is uncut pGMCSF, column C is  
30 52 bp, 453bp, 2321 bp and 4265 bp fragments of pGMCSF *EcoRI* (Eth.Br. agarose gel 0.8%). The remaining DNA was then digested with *EcoRV* (Fig. 3) and the 398-bp band containing the mGM-CSF sequence was excised and purified. In Fig. 3, column A is 1 kb DNA ladder, column B is

uncut pGMCSF, column C is 398bp, 878bp, 1443bp and 4265bp fragments of pGMCSF. Meanwhile, the pIL2 expression plasmid was linearized with *Pst*I and a sample was run on agarose gel for confirmation (Fig. 4). In Fig. 4, column A is 1kb DNA ladder, column B is uncut pIL2 and column C is linear pIL2 after *Pst*I. The remaining DNA was then deprived from any single-chain overhangs using S1 nuclease. Subsequently, the DNA was digested with *Eco*RI and the 4518-bp band containing the mIL2 cDNA sequence was excised and purified (Fig. 5). In Fig. 5, column A is 1kb DNA and column B is pIL2 4518bp Band (Eth. Br. agarose gel 0.8%). 5µl of the 398-bp DNA and 5µl of the 4518-bp DNA were run in parallel on agarose gel prior to ligation (Fig. 6). In Fig. 6, column A is 1kb DNA ladder, column B is 4518bp band of pIL2 and column C is 398bp band of pGMCSF (Eth.Br. agarose gel 0.8%). Following transformation of the ligation product in competent AH5α bacteria, 40 individual clones were screened for the presence of the fusion sequence plasmid. The collected DNA was digested with *Hind* III for a first screen of a potential clone encoding the correct fusion sequence (Fig. 7). In Fig. 7, column A is 1kb DNA ladder, columns B to L are clones 21 to 31 respectively. Expected bands for pJS330 are 738bp and 4178bp (Eth.Br. agarose gel 0.8%). Clone number 30 was identified as positive, and further used for confirmation with *Sac*I (Fig. 8). In Fig. 8, column A is 1kb DNA ladder, column B is pJS330 uncut, column C is pIL2 uncut, column D is pJS330 *Hind*III digest (expected bands 583bp and 4333bp), column F is pIL2 *Hind*III and G is pIL2 *Sac*I. (Eth.Br. agarose gel 0.8%). Fig. 9 is a restriction enzyme map of the plasmid pJS330 showing the sites used for confirmation.

The DNA of clone number 30, namely pJS330, that showed to be positive by restriction enzymes for the presence of the fusion gene, was sent for sequencing using two distinct primers. Sequencing primer 1 (P1) is complementary to a 20-bp sequence 5' of the expected glycine linker between mGM-CSF and mIL2. Sequencing primer 2 (P2) is complementary to a 20-bp sequence 5' of the start codon of mGM-CSF. Figure 10 represents the complete sequence analysis of the novel synthetic fusion transgene. In figure 10, A is the sequence analysis

obtained from P1, B is the sequence analysis obtained from P2, and C is a schematic illustration of the predicted amino acid sequence.

In order to engineer cancer cells to express this fusion gene, it has been generated a retrovector plasmid that encodes the mGMCSF/mIL2 fusion and the reporter GFP. The plasmid pJS330 was digested with *XhoI-HpaI* and the 1090-bp band containing the fusion gene was excised and purified (Fig. 11). In Fig. 11, column A is 1kb DNA ladder, column B is pJS330 uncut, column C is 1090bp and 3826bp fragments of pJS330 *XhoI-HpaI*, column D is 1kb DNA ladder, column E is AP2 uncut and column F is AP2 *BamHI* (Eth. Br. Agarose gel 0.8%). AP2 was first linearized with *BamHI*, then single-chained overhangs were filled-in, and the DNA digested with *EcoRI*. The two fragments (from pJS330 and AP2) were ligated, and the ligation product (pJS4) screened with *BglII* and *XhoI-ApaI* digests (Fig. 12). In Fig. 12, column A is 1kb DNA ladder, column B is pJS4 uncut, column C is AP2 uncut, column D is pJS4 *BglII* digest (expected bands 685bp and 7034bp), column E is AP2 *BglII* digest, column F is pJS4 *XhoI-ApaI* digest (expected bands 1233 bp and 6486bp), column G is AP2 *XhoI-ApaI* digest and column H is 1kb DNA ladder (Eth. Br. agarose gel 0.8%). Fig. 13 is a restriction enzyme map of the plasmid pJS4 showing the sites used for confirmation.

The retrovector plasmid pJS4 encoding the fusion sequence was transfected into GP+E86 packaging cells and the supernatant used to transduced GP+AM12 packaging cells. The supernatant of GP+AM12 was used to transduce B16 murine melanoma cells. The JS4- transduced B16 cells were assessed for secretion of the fusion protein by ELISA. The supernatant from B16-JS4 cells was positive for GM-CSF and IL-2 by ELISA confirming the secretion of the fusion protein (Fig. 14). In Fig. 14, A is the concentration of IL-2 produced by B16-JS4 cells, B is the concentration of IL-2 produced by non-modified B16 cells, C is the concentration of GM-CSF produced by B16-JS4 cells and D is the concentration of GM-CSF produced by naïve B16 cells. The molecular weight of the fusion protein was determined to be between 43 and 48 kilo Dalton (kD) by immunoblotting with monoclonal antibodies against mouse IL-2 or mouse GM-CSF (Fig 15). In Fig. 15, A is recombinant mouse IL-2 probed against IL-2, B is recombinant mouse GM-CSF probed against IL-

2, C is the fusion protein from B16-JS4 supernatant probed against IL-2, D is recombinant mouse GM-CSF probed against GM-CSF, E is recombinant mouse IL-2 probed against GM-CSF and F is the fusion protein from B16-JS4 supernatant probed against GM-CSF.

5 In order to confirm that the fusion protein generated from the novel fusion transgene has immuno-therapeutic uses, one million polyclonal B16-JS4 cells were injected subcutaneously into C57bl/6 mice. As a control, one million B16-AP2 cells were injected in C57bl/6 mice. After 20 days, all mice injected with control B16-AP2 cells had to be  
10 sacrificed because the mean tumor volume was more than 800 mm<sup>3</sup>. In contrast, none of the mice injected with B16-JS4 secreting the fusion protein had a tumor. By day 52 post-implantation, 3 out of 7 mice injected with B16-JS4 cells still did not show any palpable tumor while 4 out of 7 had a mean tumor volume of 25 mm<sup>3</sup> (Fig. 16). In Fig. 16, B16 murine  
15 melanoma cells were engineered in vitro to express the fusion sequence and GFP (B16-JS4) or to express GFP only (B16-AP2). The level of secretion of the fusion protein was determined in vitro by ELISA on the supernatant of B16-JS4 cells (4ng of GM-CSF/10<sup>6</sup> cells/24h and 2ng of IL-2/10<sup>6</sup> cells/24h). These tumors were then surgically removed at day  
20 52, mounted on paraffin sections and stained with hematoxylin and eosin. The immune infiltration of B16-JS4 tumors was compared to the immune infiltration of B16-AP2 tumors (Fig 17). Compared to control tumors showing minimal immune infiltration (Figs 17A and 17C), tumors secreting the fusion protein were characterized by an intense intratumoral  
25 suppurative inflammation (Figs 17B and 17D). The inflammation was diffuse through the tumor mass of all JS4 tumors and mainly consisted of neutrophils surrounding degenerated tumor cells.

The immuno-therapeutic effects of the novel synthetic fusion transgene were further compared to those of IL-2 or GM-CSF cDNA. The  
30 retrovector plasmid pIL2 (cloned in AP2) or pGMCSF was transfected into GP+E86 packaging cells and the supernatant used to transduced GP+AM12 packaging cells. The supernatant of GP+AM12 was used to transduce B16 murine melanoma cells. Clonal populations of the B16 cells thus generated to produce IL-2 or GM-CSF, as well as clonal  
35 populations of B16-JS4 cells secreting the fusion protein, were isolated.

In order to compare the immuno-therapeutic effects of the fusion protein to those of IL-2 or GM-CSF, one million clonal B16 cells secreting IL-2 (B16-IL2), GM-CSF (B16-GMCSF) or equimolar concentration of the fusion protein (B16-JS4) were injected subcutaneously into C57bl/6 mice.

- 5 As a control, one million B16-AP2 cells were injected in C57bl/6 mice. At 40 days after injection, all mice injected with B16-JS4 cells secreting the fusion protein were tumor-free, while 20% of mice injected with B16-IL2 and 100% of mice injected with B16-GMCSF had developed a tumor (Fig. 18). In Fig. 18, the level of secretion of the fusion protein was determined
- 10 in vitro by ELISA on the supernatant of B16-JS4 cells (8ng of GM-CSF/106 cells/24h and 4ng of IL-2/106 cells/24h).

### Discussion

- In the present application, it is reported the successful engineering of a DNA plasmid encoding for a chimeric protein borne from the fusion of murine GM-CSF and murine IL-2 cDNA. The fusion
- 15 sequence thereby generated was confirmed by sequence analysis using two distinct DNA primers and revealed the expected presence of a single glycine linker between the 11 amino acid-truncated 3' end of GM-CSF and the first amino acid of IL-2. When this expression plasmid was
- 20 transduced into B16 murine melanoma cells, a potent *in vivo* antitumor effect was observed despite normal cell growth *in vitro*. 52 days after the s.c. injection of  $10^6$  B16-JS4 cells, 3 out of 7 mice failed to develop any tumor. In the 4 mice that did develop cancer, the mean tumor volume was only  $25\text{mm}^3$  after 52 days. Histopathology of the tumors expressing the
- 25 GMCSF/IL2 fusion sequence revealed an intense intratumoral immune infiltration, mainly consisting of neutrophils and other granulocytes. This suggests that the novel fusion protein is strongly chemotactic for granulocytes, most likely reflecting the GM-CSF subunit activity of the chimera. It is shown herein that the IL-2 portion of the fusion protein is
- 30 responsible in part, for inhibiting tumor growth. The combined GM-CSF/IL2 have additive beneficial anti-cancer effects such as direct tumoricidal activity and immune recruitment for a "tumor vaccine" effect. It is also shown herein that the humanized version of this murine GMCSF/IL2 fusion DNA sequence will share the same characteristics in
- 35 humans with cancer. Similarly, species-specific configurations of



GMCSF/IL2 fusion gene could be used for veterinary therapeutic purposes.

5 A second application of this transgene would be as part of a genetic immunoadjuvant of a DNA vaccine for cancer or infectious diseases such as HIV, Hepatitis C or others. Co-expression of an antigen-encoding cDNA and GMCSF/IL2 fusion nucleotide sequence will lead to antigen presentation in a milieu co-generating the GMCSF/IL2 protein, where the GMCSF/IL2 will stimulate a potent immune response (Th1 and Th2) against the presented antigen. Such chimeric cytokine  
10 gene could therefore be used as a powerful genetic non-toxic adjuvant to DNA vaccination. Therapeutic use in human clinical applications, as well as agrobusiness applications such as infectious disease of commercially valuable mammals could benefit of such a powerful immunostimulatory cDNA.

15 It is also proposed that either tumor-targeted delivery of the fusion cDNA (gene) or of the recombinant protein (fusion protein) will have a therapeutic anti-cancer effect in humans. Furthermore, because it has been reported that the highest antibody titers against a DNA vaccine can be obtained when combining the expression of an antigenic peptide to the  
20 expression of GM-CSF together with IL-2, the GMCSF/IL2 fusion gene serves as a genetic tool for the generation of polyclonal and monoclonal antibodies as biotechnological reagents. Its use in its current configuration, when co-expressed with a open-reading-frame (ORF) gene, allows the generation of a potent and specific anti-ORF gene product  
25 humoral immune reaction. From these immunized animals (mice, rats, goats, etc.) splenocytes could be harvested and utilized to generate novel monoclonal antibody-producing cell lines of commercial interest.

30 While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential

features hereinbefore set forth, and as follows in the scope of the appended claims.

**WHAT IS CLAIMED IS:**

1. An immuno-therapy conjugate which comprises:  
A-c-B  
wherein:  
A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and  
c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues.
2. The conjugate as claimed in claim 1, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
3. The conjugate as claimed in claim 1, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
4. The conjugate as claimed in claim 1, wherein said interferon is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
5. An immuno-therapy fusion cDNA encoding the immuno-therapy conjugate of claim 1.

6. The fusion cDNA as claimed in claim 5, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

7. The fusion cDNA as claimed in claim 5, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

8. The fusion cDNA as claimed in claim 5, wherein said interferon is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

9. A vaccine adjuvant for DNA vaccination which comprises the conjugate of claim 1.

10. The vaccine adjuvant as claimed in claim 9, wherein said vaccination is against an infectious organism.

11. The vaccine adjuvant as claimed in claim 10, wherein said infectious organism is selected from the group consisting of: viruses, bacteria, mycobacteria, protozoa and prions.

12. The vaccine adjuvant as claimed in claim 11, wherein said virus is selected from the group of Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

13. The vaccine adjuvant as claimed in claim 9, wherein said vaccination is against malignancies, wherein said malignancies having at least one immunogen associated thereto.

14. A vaccine adjuvant for vaccination, which comprises the fusion cDNA of claim 5.

15. The vaccine adjuvant as claimed in claim 14, wherein said vaccination is against an infectious organism.

16. The vaccine adjuvant as claimed in claim 15, wherein said infectious organism is selected from the group consisting of: viruses, bacteria, mycobacteria, protozoa and prions.

17. The vaccine adjuvant as claimed in claim 16, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

18. The vaccine adjuvant as claimed in claim 14, wherein said vaccination is against malignancies, wherein said malignancies having at least one immunogen associated thereto.

19. A method for reducing tumor growth in a patient, said method comprising administering to said patient a therapeutically effective amount of the conjugate of claim 1.

20. The method as claimed in claim 19, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

21. The method as claimed in claim 19, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4,

CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

22. The method as claimed in claim 19, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

23. A method for reducing tumor growth in a patient, said method comprising administering to said patient a therapeutically effective amount of the fusion cDNA of claim 5 using a gene delivery technique.

24. The method as claimed in claim 23, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

25. The method as claimed in claim 23, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

26. The method as claimed in claim 23, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

27. The method as claimed in claim 23, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
28. A method for reducing tumor growth in a patient, said method comprising administering to said patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5.
29. The method as claimed in claim 28, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
30. The method as claimed in claim 28, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
31. The method as claimed in claim 28, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
32. A method for inhibiting a viral infection in a patient, said method comprising administering to said patient a therapeutically effective amount of the conjugate of claim 1.

33. The method of claim 32, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
34. The method as claimed in claim 32, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
35. The method as claimed in claim 32, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
36. The method as claimed in claim 32, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.
37. A method to inhibit a viral infection in a patient, said method comprising administering to said patient a therapeutically effective amount of the fusion cDNA of claim 6 using a gene delivery technique.
38. The method as claimed in claim 37, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.
39. The method as claimed in claim 37, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ ,



Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

40. The method as claimed in claim 37, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

41. The method as claimed in claim 37, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

42. The method as claimed in claim 37, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

43. A method to inhibit a viral infection in a patient, said method comprising administering to said patient a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5.

44. The method as claimed in claim 43, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

45. The method as claimed in claim 43, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
46. The method as claimed in claim 43, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
47. The method as claimed in claim 43, wherein said viral infection is selected from the group consisting of : Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.
48. A method to allow production of antigen-specific antibodies, said method comprising the administration of the species-specific fusion cDNA of claim 5 with the cDNA of the said antigen or functional fragment thereof in mammals.
49. The method as claimed in claim 48, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
50. The method as claimed in claim 48, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13,

CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

51. The method as claimed in claim 48, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

52. A method to improve immune response in a patient, said method comprising administering to said patient a therapeutically effective amount of the conjugate of claim 1.

53. The method as claimed in claim 52, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

54. The method as claimed in claim 52, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

55. The method as claimed in claim 53, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

56. Use of a therapeutically effective amount of the conjugate of claim 1 for reducing tumor growth in a patient.

57. The use as claimed in claim 56, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.
58. The use as claimed in claim 56, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.
59. The use as claimed in claim 56, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.
60. Use of a therapeutically effective amount of the fusion cDNA of claim 5 with a gene delivery technique for reducing tumor growth in a patient.
61. The use as claimed in claim 60, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.
62. The use as claimed in claim 60, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

63. The use as claimed in claim 60, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

64. The use as claimed in claim 60, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

65. Use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5 for reducing tumor growth in a patient.

66. The use as claimed in claim 65, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

67. The use as claimed in claim 65, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

68. The use as claimed in claim 65, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2,

IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

69. Use of a therapeutically effective amount of the conjugate of claim 1 for inhibiting a viral infection in a patient.

70. The use as claimed in claim 69, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

71. The use as claimed in claim 69, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

72. The use as claimed in claim 69, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

73. The use as claimed in claim 69, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

74. Use of a therapeutically effective amount of the fusion cDNA of claim 6 with a gene delivery technique to inhibit a viral infection in a patient.

75. The use as claimed in claim 74, wherein said gene delivery technique is selected from the group consisting of: recombinant viral based vectors and plasmid DNA delivery methods.

76. The use as claimed in claim 75, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

77. The use as claimed in claim 76, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

78. The use as claimed in claim 76, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

79. The use as claimed in claim 76, wherein said virus is selected from the group consisting of: Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

80. Use of a therapeutically effective amount of normal autologous patient-derived cells engineered *ex vivo* to integrate and express the fusion cDNA of claim 5 to inhibit a viral infection in a patient.

81. The use as claimed in claim 80, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-

7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

82. The use as claimed in claim 80, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

83. The use as claimed in claim 80, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

84. The use as claimed in claim 80, wherein said viral infection is selected from the group consisting of : Influenza virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, HIV, Yellow fever virus, Aphthovirus and Filovirus.

85. Use of species-specific fusion cDNA of claim 5 with the cDNA of antigen or functional fragment thereof to allow production of antigen-specific antibodies in mammals.

86. The use as claimed in claim 85, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

87. The use as claimed in claim 85, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12,



CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

88. The use as claimed in claim 85, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

89. Use of a therapeutically effective amount of the conjugate of claim 1 to improve immune response in a patient.

90. The use as claimed in claim 89, wherein said cytokine is selected from the group consisting of: GM-CSF, G-CSF, M-CSF, TNF- $\alpha$ , Angiostatin, Endostatin, VEGF, TGF- $\beta$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17 and IL-18, or a functional fragment thereof.

91. The use as claimed in claim 89, wherein said chemokine is selected from the group consisting of: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, XCL1, XCL2, CX3CL1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26 and CCL27, or a functional fragment thereof.

92. The use as claimed in claim 89, wherein said interferons is selected from the group consisting of: IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9 or a functional fragment thereof.

1 / 18




FIG. 1

2/18




FIG. 2




FIG. 3

3/18




FIG. 4




FIG. 5

4/18




FIG. 6




FIG. 7

5/18





FIG. 8

6/18

FIG. 9

7/18

Model 377	17-J5330	Signal G:98 A:185 T:99 C:140	Page 1 of 2
Version 3.3	J53primer1	DT (BD Set Any-Primer)	Fri, May 19, 2000 2:18 AM
LR-377	J5330	207BD	Thu, May 18, 2000 5:08 PM
Version 3.3.1b2	lane 17	Points 1276 to 10624 Pk 1 Loc:1276	Spacing: 11.09{11.09}

Page 1 of 2

Fri, May 19, 2000 2:18 AM

Thu, May 18, 2000 5:08 PM

Spacing: 11.09{11.09}

Signal G:98 A:185 T:99 C:140

DT {BD Set Any-Primer}

207BD

Points 1276 to 10624 Pk 1 Loc:1276

17-J5330

J53primer1

J5330

Lane 17

Model 377

Version 3.3

LR-377

Version 3.3.1b2

ABSTRACT

PRISM

[illegible][illegible]

GGACCTACAGGACTCTGAGCAGGATGGAGATTACAGGACCTGAACCTCC CAGGATGCTCACCTTCAAA TTTTACTTGGCC AAGAGGCCACAGATTGAAGATCTCAG


GCCTAGACATGAAC TTGGACCTCTCCGCCATCTTCTCTGGAT TTGACTCAAGCAAAAGCTTTCATTTGGAAGTGGCTGAGAAATTCATCAGCAATATCAGAGTACTGTTGTAAACATTA

FE-10A



8/18


Model 377 17-J5330 Signal G:98 A:185 T:99 C:140 Page 1 of 2  
 Version 3.3 J53primer1 DT (BD Set Any-Primer) Fri, May 19, 2000 2:18 AM  
 IR-377 J5330 207BD Thu, May 18, 2000 5:08 PM  
 PRISM Version 3.3.1b2 lane 17 Points 1276 to 10624 Pk 1 Loc:1276 Spacing: 11.09(11.09)



FEI-10A (Cont.)

9/18

Model 377 03-J53-30 Signal G:146 A:239 T:182 C:211 Page 1 of 2  
 Version 3.3 J53 primer 2 DT (BD Set Any-Primer) Wed, May 24, 2000 9:23 AM  
 IR-377 J53-30 207BD Tue, May 23, 2000 5:17 PM  
 Version 3.3.1b2 lane 3 Points 1129 to 10620 Pk 1 Loc: 1129 Spacing: 10.75(10.75)



FEF-108



// / 18

Mouse GM-CSF

mGM-CSF: acg (T)    mGM-CSF: ggc (G)  
sequenced as aca (T)    sequenced as cgc (R)

20 bases Sequencing P2

...S A T G L R S R A Q A S

Mature Protein

Signal peptide

M W L Q N L L F L G I V V Y S L S A P T R S P I T V T R P W K H V E A I K E A L N L L

D D M P V T L N E E V E V S N E F S F K K L T C V Q T R L K I F E Q G L R G N F T

20 bases Sequencing P1

K L K G A L N M T A S Y Y Q T Y C P P T P E T D C E T Q V T T Y A D F I D S L K T F L

T D I P F E C K K P S Q K

Excised 11 a.a.

EcoRV site

Pst I site

(ggc) (atg)



Mouse INTERLEUKIN-2

G — M Y S M Q L A S C V T L T L V L L V N S A P T S S S T S  
S S T A E A Q Q Q Q Q Q Q Q Q Q H L E Q L L M D L Q E L L S R M E N Y R N L K L P  
R M L T F K F Y L P K Q A T E L K D L Q C L E D E L G P L R H V L D L T Q S K S F Q L E  
D A E N F I S N I R V T V V K L K G S D N T F E C Q F D D E S A T V V D F L R R W I A F C  
Q S I I S T S P Q ----


(taa)

FIG. 10C


12/18

FIG. 11FIG. 12

13/18

FIG. 13

14 / 18

FIG. 14

15 / 18

D E F

50kd

20kd

A B C

50kd


21kd

FIG. 15

SUBSTITUTE SHEET (RULE 26)




16/18

FIG. 16

17/18

2X

FIG. 17B




40X

FIG. 17D

2X

FIG. 17A




40X

FIG. 17C



SUBSTITUTE SHEET (RULE 26)

18/18

FIG. 18

## SEQUENCE LISTING

<110> Galipeau, Jacques

Stagg, John

Centre for translational research in cancer

<120> A novel synthetic chimeric fusion

transgene with immuno-therapeutic uses

<130> 14226-10 PCT FC/VC

<150> US 60/330,476

<151> 2001-10-23

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> sequencing primer

<400> 1

acagccagct actaccagac

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> sequencing primer

<400> 2

cgctaccgga ctcagatctc

20



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 03/035105 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/535**,  
14/55, C12N 15/62, A61P 35/00

(21) International Application Number: PCT/CA02/01649

(22) International Filing Date: 23 October 2002 (23.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/330,476 23 October 2001 (23.10.2001) US

(71) Applicant (*for all designated States except US*): **CENTRE  
FOR TRANSLATIONAL RESEARCH IN CANCER**  
[CA/CA]; 3755 chemin de la Côte Ste-Catherine, Montréal,  
Québec H3T 1E2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **GALIPEAU,**  
**Jacques** [CA/CA]; 251, Morrison, Town of Mount-Royal,  
Québec H3R 1K7 (CA). **STAGG, John** [CA/CA]; 5245  
Côte Ste-Catherine, Apt. 14, Montréal, Québec H3W 1M9  
(CA).

(74) Agent: **OGILVY RENAULT**; Suite 1600, 1981 McGill  
College Avenue, Montreal, Québec H3A 2Y3 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
18 September 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A SYNTHETIC CHIMERIC FUSION PROTEIN WITH IMMUNO-THERAPEUTIC USES

(57) Abstract: The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response in a patient.

WO 03/035105 A3

International Application No  
PCT/CA 02/01649

IPC 7 C07K14/535 C07K14/55 C12N15/62 A61P35/00

IPC 7 C07K C12N

EPO-Internal, WPI Data, PAJ, EMBASE, MEDLINE, BIOSIS, SEQUENCE SEARCH

## Renggli, J



## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SANG GOO LEE ET AL: "EFFECT OF GM-CSF AND IL-2 CO-EXPRESSION ON THE ANTI-TUMOR IMMUNE RESPONSE"  ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR,  vol. 20, no. 4, July 2000 (2000-07), pages 2681-2686, XP009003638  ISSN: 0250-7005</p> <p>the whole document</p>	<p>1,2,5,6,  9-20,  23-25,  28,29,  32,33,  36-39,  42-44,  47-49,  52,53,  56,57,  60-62,  65,66,  69,70,  73-76,  79-81,  84-86,  89,90</p>
Y	<p>TSENG SHENG-HONG ET AL: "Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain."  CANCER GENE THERAPY,  vol. 6, no. 4, July 1999 (1999-07), pages 302-312, XP002246331  ISSN: 0929-1903</p> <p>abstract</p>	<p>1,2,5,6,  9-20,  23-25,  28,29,  32,33,  36-39,  42-44,  47-49,  52,53,  56,57,  60-62,  65,66,  69,70,  73-76,  79-81,  84-86,  89,90</p>

-/--

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/01649

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>VILE R G ET AL: "CANCER GENE THERAPY: HARD LESSONS AND NEW COURSES" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 1, January 2000 (2000-01), pages 2-8, XP008010621 ISSN: 0969-7128</p> <p>page 3 -page 6</p>	<p>1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90</p>
Y	<p>GIOVANNI DE C ET AL: "The prospects for cancer gene therapy" INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 22, no. 12, December 2000 (2000-12), pages 1025-1032, XP002218907 ISSN: 0192-0561</p> <p>abstract</p> <p>--- -/--</p>	<p>1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90</p>

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MAECKER H T ET AL: "DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 15, 1 October 1997 (1997-10-01), pages 1687-1696, XP004091940 ISSN: 0264-410X</p> <p>the whole document _____</p>	<p>1,2,5,6, 9-20, 23-25, 28,29, 32,33, 36-39, 42-44, 47-49, 52,53, 56,57, 60-62, 65,66, 69,70, 73-76, 79-81, 84-86, 89,90</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 02/01649

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: see reasoning  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claims 19, 20, 23-25, 28, 29, 32, 33, 36-39, 42-44, 47-49, 52, 53, 56, 57, 60-62, 65, 66, 69, 70, 73-76, 79-81, 84-86, 89, 90 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## Continuation of Box I.2

Claims Nos.: see reasoning

Present claims 1-92 relate to an extremely large number of possible conjugates and uses/methods thereof. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of said conjugates claimed, namely for a SINGLE fusion protein comprising interleukin-2 and GM-CSF.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to conjugates comprising interleukin-2 and GM-CSF.

Claims 3, 4, 7, 8, 21, 22, 26, 27, 30, 31, 34, 35, 40, 41, 45, 46, 50, 51, 54, 55, 58, 59, 63, 64, 67, 68, 71, 72, 77, 78, 82, 83, 87, 88, 91 and 92 have consequently NOT been searched.

The remaining claims have been only partly searched, insofar as they relate to a conjugate comprising IL2 and GM-CSF.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

tion on patent family members

International Application No

PCT/CA 02/01649

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5359035	A	25-10-1994	
		DE 3545568 A1	16-07-1987
		DE 3712985 A1	03-11-1988
		AT 71144 T	15-01-1992
		AU 637139 B2	20-05-1993
		AU 6268390 A	13-12-1990
		AU 601959 B2	27-09-1990
		AU 6675686 A	25-06-1987
		CA 1341197 C	06-03-2001
		DE 3683267 D1	13-02-1992
		DK 619086 A	22-06-1987
		EP 0228018 A2	08-07-1987
		ES 2055686 T3	01-09-1994
		FI 865186 A ,B,	22-06-1987
		GR 3003999 T3	16-03-1993
		HU 44615 A2	28-03-1988
		IE 59779 B1	06-04-1994
		IL 81020 A	27-11-1995
		JP 2575367 B2	22-01-1997
		JP 62164695 A	21-07-1987
		KR 9405585 B1	21-06-1994
		NO 865191 A ,B,	22-06-1987
		PT 83972 A ,B	01-01-1987
		US 5298603 A	29-03-1994
		ZA 8609557 A	28-10-1987
		AT 79135 T	15-08-1992
		AU 613022 B2	25-07-1991
		AU 1466188 A	20-10-1988
		CA 1322157 C	14-09-1993
		DE 3873397 D1	10-09-1992
		DK 209188 A	17-10-1988
		EP 0288809 A1	02-11-1988
		ES 2033981 T3	01-04-1993
		FI 881743 A ,B,	17-10-1988
		GR 3006141 T3	21-06-1993
		HU 47319 A2	28-02-1989
		IE 61574 B1	16-11-1994
		IL 86086 A	24-01-1995
		JP 2667193 B2	27-10-1997
		JP 63301898 A	08-12-1988
		KR 9700187 B1	06-01-1997
		NO 881658 A ,B,	17-10-1988
		NZ 224247 A	26-04-1990
		PH 25327 A	30-04-1991
		PT 87237 A ,B	01-05-1988
		ZA 8802659 A	14-10-1988

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**